Hiccups are one of the stranger complaints attached to this drug class, and the strangest thing about them is where they turn up. They are printed on a current U.S. label as an adverse reaction. They are absent from every published study of these drugs. And no document anywhere — label, database or paper — states how often they happen. That combination is unusual enough to be worth laying out precisely.
One label names it, and six do not
Seven current labels in this class were read for the word. The Wegovy label carries it, in the Adverse Reactions section at §6.1, under the subheading on gastrointestinal reactions: other reactions occurring at a higher incidence among treated adults included dyspepsia, abdominal pain, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, gastritis, hemorrhoids, and hiccups, most frequently reported during dosage escalation.[1]
The Ozempic injection label does not name it. Neither does the combined label for the oral semaglutide tablets, nor Mounjaro, nor Zepbound, nor Saxenda, nor Trulicity.[2] So the symptom sits on exactly one document in a class of seven, and it is the document that covers the newest weight-management product. The incidence tables the other labels do publish are summarized in the side-effects article, and hiccups appear in none of them.
The number that is missing is missing on purpose
Read the Wegovy paragraph again and the asymmetry is hard to miss. The same few sentences report that 73% of treated adults and 47% on placebo had a gastrointestinal reaction, that severe ones ran 4.1% against 0.9%, and that the most frequent were nausea (44% versus 16%), vomiting (25% versus 6%) and diarrhea (30% versus 16%).[1] Then it changes register and lists hiccups among reactions that merely occurred more often, with no figure of any kind.
That is how a label handles an event that cleared the threshold for mention and not the threshold for tabulation. It is a real signal reported honestly at the resolution the data support. It is also why every page on the internet quoting a percentage for hiccups on these drugs is quoting something that does not exist.
What the reporting database holds
The FDA Adverse Event Reporting System is the only place a count exists, and a count is all it is. Queried through the openFDA interface on September 15, 2026, against data last updated July 30, 2026, the whole database holds 8,051 reports carrying the reaction term Hiccups. Of those, 205 name a semaglutide product and 107 name a tirzepatide product.[3]
Ranked against every other reaction term reported for the same drugs, Hiccups sits 226th of the 500 terms returned for semaglutide and 312th of 500 for tirzepatide, far below nausea and vomiting at the top.[3] Those are the same reports that drive the belching signal described in the sulfur-burps article, and the contrast is instructive: belching is uncommon in the raw counts but extraordinary once adjusted for how often it is reported about drugs generally. Nobody has run that adjustment for hiccups in this class, so the ranking above is a frequency observation and nothing more.
The brand split is the part to be careful with. Ozempic accounts for 179 of the semaglutide reports and Wegovy for 30; Mounjaro accounts for 55 and Zepbound for 48.[3] It would be easy to read that as the injections for diabetes causing more hiccups, and it is not evidence of that. These products entered the market years apart, at very different volumes, with very different patient populations and very different levels of press attention — all of which move report counts and none of which the database records. The product whose label names the symptom is the one with the fewest reports of it.
Why a count can never become a rate here
A spontaneous-reporting system collects the numerator and never the denominator. Nobody knows how many people took the drug, how many had hiccups and said nothing, or how many reports describe the same event twice. The FDA attaches its own caution to the data, and the labels attach the standard version of it to their postmarketing sections: reactions reported voluntarily from a population of uncertain size cannot have their frequency reliably estimated.[1]
So the honest statement is narrow. More than two hundred people or their clinicians have told the FDA that someone taking semaglutide had hiccups. That is a fact about reports. It is not a fact about risk, and the two get confused constantly on pages selling these drugs — most of which dispense compounded versions that are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before dispensing, and that generate no labeled adverse-reaction table of their own.
The one thing the database has established about hiccups is about sex
Drug-induced hiccups have been studied in FAERS directly, just not for this class. An analysis of 11,810,863 adverse drug reactions reported from the first quarter of 2004 through the first quarter of 2020 extracted 1,454 reports of hiccups. Of those, 1,159 involved males and 257 involved females, with sex unknown in 38.[4] Roughly four and a half reports in five described a man.
The authors ran multivariable analysis and found nicotine products the key suspect drug for both sexes, with older age, lower body weight, nicotine and fourteen other drugs as independent risk factors in males against only nicotine and three others in females. They concluded the mechanism is strongly related to sex.[4] A follow-up from the same group used the same database to look for the molecular events that might start the process, and described the pathogenesis of drug-induced hiccups as still unknown with limited evidence on treatment or prevention.[5]
Two things follow. No drug in this class was among the suspects those analyses extracted, though several were on the U.S. market for the whole period. And the demographic that dominates hiccup reporting is close to the opposite of the one that dominates direct-to-consumer weight-loss prescribing, a difference traced in the sex-differences article.
The mechanism people assume, and why it is an assumption
A hiccup is a reflex, not a symptom of the stomach. The arc runs through afferent fibers in the phrenic and vagus nerves and the sympathetic chain, a poorly localized processing center in the brainstem, and efferent output to the diaphragm and the glottis — which is why the clinical literature treats persistent hiccups as a reason to look for a cause along that whole path rather than in one organ.[6]
Gastric distension is a recognized trigger within that arc, and reflux disease is strongly associated: one review puts hiccups at 0.05% of general inpatients and up to 10% of patients with gastroesophageal reflux disease.[7] That is the route people reach for, because these drugs do slow gastric emptying and do raise reflux reporting, as the reflux article sets out. But the 10% figure is a fact about reflux patients, not about anybody on a GLP-1, and nothing published connects the two. The chain is plausible and unmeasured, which is a different thing from established.
The distinction that actually matters clinically
The hiccup literature divides the problem by duration rather than by cause, and that division carries the only consequential difference here. Acute hiccups resolve on their own and are often stopped by physical maneuvers. Persistent and intractable hiccups — lasting days or months — are rare, can be distressing, and are treated most effectively by treating whatever underlies them.[6]
A systematic review found reported treatment of 341 patients with persistent or intractable hiccups across 15 published studies, and no adequately powered, well-designed trial of any treatment. Baclofen and metoclopramide were supported by small randomized placebo-controlled trials, with observational data behind gabapentin and chlorpromazine.[6] Persistent hiccups have also been the presenting sign of serious unrelated conditions often enough that the review literature treats them as a reason for diagnostic work rather than a nuisance to be suppressed.[8]
That is the part a commerce page should not blur. Hiccups that come and go during dose escalation are the thing the Wegovy label describes. Hiccups that run for days without stopping are a separate clinical situation with its own workup, and the difference belongs to a prescriber rather than to a seller’s symptom page.
What is left after all that
Three statements survive. Hiccups are a labeled adverse reaction of one product in this class, reported most often during dose escalation. Two hundred and five spontaneous reports name a semaglutide product and a hundred and seven name a tirzepatide product, which establishes that the event gets reported and nothing about how often it occurs. And a search of published titles and abstracts for hiccups alongside any drug in this class returns no records at all.[3]
Everything past that is inference. No study has measured whether these drugs cause hiccups, at what rate, in whom, or by what route; no guidance document addresses it; and the general hiccup literature that does exist was written about other drugs and other patients. Nausea and vomiting, which the same labels do quantify, are the events with an evidence base behind them, and the vomiting article carries those figures. This one exists to record an absence accurately rather than to fill it.